1 CagriSema 2.4 mg 2.4 mg FDA NDA filing; Novo Nordisk data on file., 2 Garvey WT, Blher M, Osorto Contreras CK, et al. Coadministered cagrilintide and semaglutide in adults with overweight or Three new #GLP 1 drugs for obesity treatment2 injectables and 1 pillmay receive FDA approval this year. Here's how high dose semaglutide, cagrilintide plus semaglutide, and orforglipron performed in phase 3 trials. CagriSema Dual Pathway Metabolic Signaling Compound CagriSema combines two investigational molecules Cagrilintide (amylin analogue) and Semaglutide (GLP 1 receptor agonist), designed to influence key metabolic and appetite regulating pathways. Current Latest science on Cagrilintide from Novo Nordisk